Side-by-side · Research reference
GHRP-6vsKisspeptin-10
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED10/36 cited
BPhase 2HUMAN-REVIEWED10/41 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
Kisspeptin-10
Neuropeptide · GPR54 Agonist
Phase 1/2Clinical stage
IV / SQ · Investigational
01Mechanism of Action
Parameter
GHRP-6
Kisspeptin-10
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026Collado-Sole 2026
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026Rønnekleiv 2026
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026
Feedback intact?
—
Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026Rønnekleiv 2026
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
Kisspeptin-10
Frequency
1–3× per day
—
Lower / starter dose
50 mcg per dose
—
Duration
8–12 weeks on / 4 off
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-meal preferred for appetite support
—
Half-life
~15 minMalagón 1999
Short (minutes)
Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.
Clinical trial dose
—
Phase 1/2 investigational
Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).
Route
—
IV or SQ administration
IV preferred in controlled trials for precise pulsatile delivery.
04Side Effects & Safety
Parameter
GHRP-6
Kisspeptin-10
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
Erythema, mild discomfort (SQ route)
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Ovarian hyperstimulation
—
Theoretical risk with supraphysiological dosing in fertility protocols
Headache
—
Mild, reported in early-phase trials
Nausea
—
Transient GI symptoms with IV bolus
Hot flashes
—
Vasomotor symptoms from LH surge
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Kisspeptin-10
- ·Active pregnancy
- ·Hormone-sensitive malignancy (breast, ovarian, endometrial)
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
Kisspeptin-10
- ·Polycystic ovary syndrome (PCOS) without monitoring
- ·Uncontrolled thyroid dysfunction
05Administration Protocol
Parameter
GHRP-6
Kisspeptin-10
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.
2. Injection site
SQ — abdomen. Rotate sites.
IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.
5. Needle
29–31G, 4–8 mm insulin syringe.
Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.